News

We will attend Cphi India, Pmec at the India Expo Centre,Greater Noida,Delhi NCR,india Our booth no is 14.A50. Welcome to visit us.

Welcome to visit us at booth no 2C20 at Madriad, Spain from Oct 9 to 13 th

Meet us on Worldwide Cphi from Oct 9th to Oct 11th at Mardrid,Spain. Booth no 2C20.

We will attend CPHI China 2018 from June 20th to 22th. booth no is N5E30. welcome visit and see you at SNICE.

CPhI Barcelona Oct. 4-6, 2016 Barcelona, Spain Zhengli at CPhI Barcelona: glass pharmaceutical packaging to meet customers' requirements Zhengli is one of the top suppliers in China market for manufacturing of glass pharmaceutical vials, pre-fillable syringes, cartridges, ampoules and other glass containers. And Zhengli is about to enter international market this year. At CPhI Barcelona, Zhengli showed its vials, pre-fillable syringes, cartridges and ampoules to the pharmaceutical industry, buyers and visitors. Based on over 25-year experience of vials manufacturing, with top-of-the-range production and inspection lines, Zhengli products represent design, quality, professional and continuous improvement. Zhengli vials, pre-fillable syringes, cartridges and ampoules are made of high quality type I, II and III clear and amber borosilicate glass. With full range of pharmaceutical packaging products, state-of-the-art production lines and strong R&D team, Zhengli has already built high-end brand and market leader in China market. Now, Zhengli is ready to contribute to customers` growth all over the world.

28 October 2014 08:26 Source:ICIS News By Ajoy K Das KOLKATA (ICIS)--India has imposed a ban on the use of plastic packaging for liquid pharmaceutical formulations, and the domestic pharmaceutical industry was given six months to make the switch to glass packaging, a government official said on Tuesday. According to players in the domestic plastics industry, it is too early to assess the loss of business from this newly implemented regulation. In a notification issued on 19 October, India`s Ministry of Health said: [No pharmaceutical manufacturer shall use PET or plastic containers for packing liquid oral formulations for primary packaging of drug formulations for use by pediatric, geriatric and women of reproductive age." The Indian pharmaceutical packaging material industry is valued at around $23bn and is growing at annualized rate of 15%. The polyethylene terephthalate (PET) bottle industry used for packing beverages and pharmaceuticals was estimated at $1.6bn and, prior to the ban, was forecast to grow to $2.15bn by 2016. The ban on plastic bottles for pharmaceutical use was imposed upon the recommendation of the country`s Drug Technical Advisory Board (DTAB) early this month. India had started looking into the adverse effects of using PET in pharmaceutical packaging in early 2013. Several representations were made before the health ministry and DTAB on health hazards of using polyethylene terephthalate (PET) bottles for packing liquid medications such as suspensions and syrups. Drug manufacturers represented by bodies like Goa Pharmaceutical Manufacturers Association (GPMA) had argued that PET was widely used in as packaging material for pharmaceutical products even in high developed and regulated markets like UK, US and Japan. But it was established that plastic packaging has an adverse effect on humans due to presence of endocrine disruptors, which refer to chemicals that can interfere with the hormone system,according to the health ministry official. DTAB, in its report, concluded that Indian environmental conditions were very different from those in developed and regulated markets, and with temperatures rising to as high as 45-50 degree centigrade in most parts of the country, risks of degradation from use of plastic packaging was much higher, the ministry official said. The pharmaceutical industry has been given six months from the date of the ministry notification to make the switch to glass bottles, which are more expensive than PET packaging, but ensures higher stability and efficacy of liquid formulations, the official said. No such objections on the use of PET were raised on food packaging, the official said.

Joe Reynolds thinks so. As research manager in Noble`s design and engineering department, Reynolds helps drug and medical device manufacturers develop training aids that can help patients learn how to self-administer therapies. Some of these aids can be incorporated into packaging, and they could provide additional support when patients experience situations such as needle anxiety or training decay. "We focus on ways to build confidence levels to self-administer products, and we have different ways to decrease anxiety as well as address training decay, which can happen with drugs that are taken on a weekly, bimonthly, or quarterly basis," explains Reynolds. [We try to make additional touch points to help patients learn or relearn key steps to adhere to therapy." Noble follows [an integrated product development process that identifies the unique training needs of patients and other stakeholders," says Reynolds. [We develop product requirements, create concepts that tie to user needs, and test those concepts through user feedback." Within packaging, different platform technologies are possible, he says. Designs could provide [multisensory feedback, such as auditory features or LEDs that correspond to a spoken script," he explains. [We have sensors that we incorporate that can wirelessly connect with training devices to teach patients how to avoid mistakes." Smart Pad 2.0 is one such approach. Launched in October 2015, Smart Pad 2.0 incorporates sensors and other onboard technology into injection pads built into the the packaging. [The onboard technology can detect mistakes and provides an active learning experience," Reynolds says. [The additional level of support increases learning retention." It can be used with different injection devices and programmed with different languages, he adds. Noble presented Smart Pad 2.0 at the PDA Universe of Prefilled Syringes & Injection Devices in Vienna.

The packaging industry plays a major role in the pharmaceutical market. It not only provides containment and drug safety, but also ensures identity, convenience of handling, and delivery. It needs to balance complex considerations. Pharmaceutical packaging firms are some of the industry's most innovative companies, as has been evident in the last 10 years. Packaging is a science and has been continuously evolving. In 2014, the pharmaceutical industry has had a variety to choose from (including the prototypes). Europe and other developed markets have become increasingly vigilant in tracking pharmaceutical packaging and stopping drug counterfeit. By 2017, serialization of drug packages will be mandatory for all manufacturers. Under these circumstances, drug manufacturers have limited or no choice but to comply with the new norms if they want to continue operating in these markets. Pharmaceutical packaging plays an important role in saving costs. By using the latest technologies, drug manufacturers can switch from their existing packaging forms to more innovative designs without spending too much money on R&D. Packaging firms have been always the greatest supporters of the pharmaceutical industry and play a major role in reducing costs. Amcor, CCL Industries, Schott, and MeadWestvaco are some of the major names in the pharmaceutical packaging industry. These firms have been responsible for introducing innovations in pharmaceutical packaging. Some of the ready-for-use prototypes are expected to create a major change in the way drugs will be packaged going forward.

InnoPack Worldwide is the leading European show for pharmaceutical packaging and drug delivery systems, born out of the success of ICSE`s Packaging Zone. It brings together buyers and specifiers from the packaging and pharmaceutical industries, creating business opportunities through a dedicated worldwide forum. InnoPack offers innovative and diverse solutions to meet the increasing demand for new ways to package and deliver medication in accordance with patient compliance adherence. InnoPack is taking place on 4-6 October, 2016 at Fira de Barcelona Gran Via, Barcelona, Spain. During this 3-day pharma show dedicated to pharmaceutical packaging, attendees will have an opportunity to meet pharma industry leaders, suppliers and innovators. The expo features a special Labelling Zone, exclusively for firms providing labelling, anti-counterfeiting and track and trace solutions. Zhengli Pharmaceutical Packaging will show its wide range of products including glass prefilled syringes, cartridges, ampoules, vials for pharmaceuticals, labs and also cosmetics. See you in Barcelona 4-6 Oct. 2016.

Global demand for primary pharmaceutical containers including pharmaceutical vials, pharmaceutical cartridges, pharmaceutical ampoules and pharmaceutical prefillable syringes, will increase 6.6 percent annually to over $57 billion in 2017. Prefillable syringes, notes the report, will be in high demand, and the list of suppliers and vendors pursuing the potential revenue from this category are becoming legion; Becton Dickinson , Gerresheimer, SCHOTT, Vetter West, Zhengli, Weigao (to name just a few top players) are all positioning themselves strategically and operationally to deliver solutions to meet this burgeoning demand. Demand for prefillable, injectable, single unit dose forms is being driven by a number of factors but the advances in the biotechnology sector will mean a steady stream of parenteral therapies requiring prefillable solutions to deliver these therapies to consumers. Players are seeing growing demand from customers for pure, high-quality packaging components for injectable biologics and biosimilars.

The Freedonia Group projects world demand for pharmaceutical packaging products to increase 6.5 percent annually to over $101 billion in 2019. Because of advanced and diverse drug-producing industries, almost 60 percent of global demand will exist in the developed economies of Canada, Japan, the US, and Western Europe. India and China will form the fastest growing markets due to rapidly expanding pharmaceutical manufacturing capabilities and the adoption of more stringent regulations aimed at improving the quality and integrity of domestically produced medicines. Brazil, Mexico, Turkey, and various other countries of the Asia/Pacific, Central and South America, and Africa/Mideast regions are among developing markets that are expected to expand and diversify drug-producing industries and register above average gains in pharmaceutical packaging product demand.

CPhI China June 21 – 23, 2016 Shanghai, China Booth W5F30 Zhengli at CPhI China: glass pharmaceutical packaging to meet customers' requirements Zhengli is one of the top suppliers in China market for manufacturing of glass pharmaceutical vials, pre-fillable syringes, cartridges, ampoules and other glass containers. And Zhengli is about to enter international market this year. At CPhI China, Zhengli showed its vials, pre-fillable syringes, cartridges and ampoules to the pharmaceutical industry, buyers and visitors. Based on over 25-year experience of vials manufacturing, with top-of-the-range production and inspection lines, Zhengli products represent design, quality, professional and continuous improvement. Zhengli vials, pre-fillable syringes, cartridges and ampoules are made of high quality type I, II and III clear and amber borosilicate glass. With full range of pharmaceutical packaging products, state-of-the-art production lines and strong R&D team, Zhengli has already built high-end brand and market leader in China market. Now, Zhengli is ready to contribute to customers` growth all over the world. Phone: +86 574 8757 6668 Fax: +86 574 8757 6699 E-Mail: sales@nbzhengli.com

Vaccines and injectable biologics are not always used in perfect environments. Indeed, they regularly need to be deployed in emergency situations or in remote areas to respond to outbreaks of disease. Prefilled syringes are often better suited to these applications due to the speed at which they can be delivered and the fact that less specialism is needed for tasks like drug reconstitution. Medical professionals have responded positively to the benefits of prefilled technologies, as in studies by prefilled syringe market leader Becton Dickinson, as many as nine out of ten healthcare professionals preferred prefills to standard syringes. For healthcare providers, the fact that prefilled syringes come ready to use with the exact drug dosage required is a major advantage, minimising the potential for dosage errors. Providing prefilled needles with exact dosages is not only convenient for medical users, it also prevents a huge amount of drug wastage for pharmaceutical companies. Typically, multidose or single-dose vials have a drug overfill of 20-25% to ensure the drug administrator always has enough to fill the correct dose and to account for human errors. The virtual elimination of overfill by prefilled syringes eradicates a major source of inefficiency in the manufacturing process, allowing larger quantities of drugs (the production of which is often highly expensive) to be sold and used.